Major Factors Revamping Asian Biopharma Supply Chain

The landscape is changing rapidly for Asia’s biopharma sector, which has been thrust to the center of the battle against COVID-19.

FREMONT, CA: Most pharma have complex supply chains under-utilized, inefficient and ill-armed to cope with the sort of products coming down the pipeline. A new report predicts that to meet the demands of a fast-evolving marketplace and the transformation from patient to outcome, the pharma supply chain will require a radical overhaul. Several forces are reshaping the environment in which the sector operates and dictating the need for a different supply chain. Here are some major trends that are shaping the Asian biopharma supply chain. 

• Making Medicines Faster and Cheaper 

Making medicines faster and cheaper is a new normal. But against the debate on quality and cost, the broader innovation is only accelerating. As big global firms ramp up output, the requirement for technology that boosts productivity should grow. Smaller companies are stepping up to take bigger roles. The objective to bring new products to market faster is reflected across Asia. There is major investment across all sub-sectors of healthcare start-ups, comprising med-tech and biopharma, where players are expected in fields like the cell, gene therapies and small molecules.

• Environmental-Friendly Packaging

Consumers are now expecting products manufactured and delivered through sustainable processes from sustainable firms. And while pharma packaging presents waste issues, more sustainable solutions are on the rise, especially in the most challenging temperature range to sustain. Similarly, active temperature-controlled speciality containers, which avoid the need for gel packs or dry ice, will remain in demand – especially for transporting temperature-sensitive active pharmaceutical ingredients.

• Better Manufacturing Agility

As the race to discover, develop and market medicine increases, examples of differentiated, value-specific supply chains for various product types appear everywhere. The COVID-19 pandemic highlighted the need for agility. Fears over severe shortages of antibiotics and medicines have increased. With the prolonged closure of China’s factories, the vulnerability of the pharma supply chain became evident. The pharma supply chain, including biopharma, will need the flexibility to manage its supply chain.

See Also :- Top Tech Solutions for Healthcare